Loss-of-function mutations in SLC13A5 have been associated with early-onset epilepsy, but the role of citrate metabolism in the pathophysiology of these patients is not well understood (Hardies et al., 2015; Klotz et al., 2016; Thevenon et al., 2014). The gene discussed is SLC13A5; the disease is epilepsy.